| Literature DB >> 26409404 |
Antonino Naro1, Antonino Leo1, Serena Filoni2, Placido Bramanti1, Rocco Salvatore Calabrò1.
Abstract
PURPOSE: The unresponsive wakefulness syndrome (UWS) is characterized by either a profound unawareness or an impairment of large-scale cortico/subcortical connectivity. Nevertheless, some individuals with UWS could show residual markers of consciousness and cognition. In this study, we applied an electrophysiological approach aimed to identify the residual visuomotor connectivity patterns that are thought to be linked to awareness, in patients with chronic disorder of consciousness (DOC).Entities:
Keywords: DLPFC; MCS; UWS; functional connectivity; parieto-occipital area; tDCS; visuomotor integration
Mesh:
Year: 2015 PMID: 26409404 PMCID: PMC4923741 DOI: 10.3233/RNN-150525
Source DB: PubMed Journal: Restor Neurol Neurosci ISSN: 0922-6028 Impact factor: 2.406
The Clinical and demographic characteristics of the whole sample. We reported the individual CRS-R mean values ± sd (the CRS-R was daily administered for 30 consecutive days before the protocol enrollment). We marked in bold the patients who showed a visuo-motor improvement after the real_protocol application
| DOC | gender | etiology | age | BI | MRI | CRS-R | ||||||
| total | A | V | M | OM | C | Ar | ||||||
| MCS | F | A | 72 | 6 | WMH | 18 ± 0.7 | 4 ± 1.4 | 4 ± 0.6 | 5 ± 1.9 | 1 ± 1.8 | 1.8 ± 0.9 | 3 ± 1.3 |
| M | T | 51 | 18 | WMH, RBG_h | 15 ± 1.6 | 3 ± 1.5 | 3 ± 0.9 | 4 ± 1.7 | 1 ± 1.2 | 0.6 ± 0.3 | 3 ± 0.8 | |
| F | A | 66 | 9 | WMH | 12 ± 1.7 | 1 ± 0.9 | 3 ± 1.2 | 2 ± 0.8 | 2 ± 0.7 | 1.6 ± 0.9 | 3 ± 0.9 | |
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
| |
| F | A | 41 | 15 | WMH | 12 ± 1 | 1 ± 0.5 | 1 ± 0.6 | 3 ± 0.5 | 2 ± 0.3 | 0.6 ± 0.4 | 3 ± 1.9 | |
| M | T | 35 | 16 | WMH, RBG_h | 11 ± 0.2 | 1 ± 1.8 | 1 ± 1.7 | 3 ± 0.7 | 2 ± 1.8 | 1.7 ± 0.6 | 3 ± 0.1 | |
|
|
|
|
|
|
|
|
|
|
| |||
| UWS | M | A | 53 | 8 | WMH | 5 ± 0.4 | 1 ± 1.1 | 1 ± 1.2 | 1 ± 1.1 | 1 ± 0.6 | 0.4 ± 0.1 | 1 ± 1.5 |
| F | T | 26 | 3 | DAI, SAH | 4 ± 1.4 | 1 ± 0.7 | 1 ± 0.8 | 1 ± 1.5 | 0 ± 1.4 | 1.3 ± 1 | 1 ± 0.6 | |
|
|
|
|
|
|
|
|
|
|
|
|
| |
| F | A | 62 | 11 | WMH | 6 ± 1 | 1 ± 1.3 | 1 ± 1.2 | 2 ± 0.6 | 0 ± 0.3 | 0.8 ± 0.9 | 2 ± 0.4 | |
| M | T | 61 | 9 | SAH | 4 ± 0.7 | 1 ± 1 | 1 ± 0.2 | 1 ± 0.2 | 0 ± 1.2 | 1.1 ± 0.2 | 1 ± 1.6 | |
| M | A | 69 | 11 | WMH | 7 ± 1.3 | 1 ± 0.1 | 1 ± 0.7 | 2 ± 0.7 | 1 ± 1.1 | 1.4 ± 0.6 | 2 ± 0.9 | |
| F | T | 74 | 12 | DAI, SAH | 6 ± 0.3 | 1 ± 1.4 | 2 ± 1.4 | 1 ± 1.4 | 0 ± 0.7 | 0.4 ± 0.6 | 2 ± 1.4 | |
|
|
|
|
|
|
|
|
|
|
| |||
Etiology: A, post-anoxic, T, post-traumatic brain injury; BI: brain injury onset in months; age in years; MRI: structural patterns including WMH (white matter hyper-intensity), _h (hemorrhagic lesion), RFP (right fronto-polar), RBG (basal ganglia), LFb (left fronto-basal), SAH (sub-arachnoid hemorrhage), DAI (diffuse axonal injury); CRS-R: Coma Recovery Scale-revised including auditory (A), visual (V), motor (M), oro-motor (OM), communication domain (C), and arousal induction (Ar); sd: standard deviation.
Fig.1Summarizes the experimental design. We carried the clinical (CRS-R) and the electrophysiological measurements (single pulse – sp-, paired-pulse – pp-, dual-site – ds- TMS, and visuomotor integration -VMI) before (TPRE) and after (T0, T30, and T60) each conditioning protocol: real_protocol, sham_protocol, tDCS_alone, and tACS_alone.
The comparison among electrophysiological parameters in HC, MCS and individuals with UWS. We found significant differences between MCS and UWS (pMCS/UWS), and DOC and HC ( *) (each unpaired t-tests, p < 0.05, except for RMT% , MEP amplitude, VEP amplitude and latency). UWS patients did not show ERPs, with a global impairment of cortical excitability, connectivity, and VEP latency and amplitude. MCS displayed an increase of cortical excitability (increased VMI100, SICF, PMv, and PPC; reduced VMI40, PMd, SMA, and LICI), a partially preserved premotor-motor and VMI connectivity, and the presence of ERPs limited to LO electrode. Some MCS/UWS differences approached the statistical significance (labeled as NS). Data are reported as mean ± se
| Measures | HC | MCS | UWS | PMCS/UWS | |
| sp | RMT (%) | 55 ± 3 | 58 ± 2 | 60 ± 9 | NS |
| MEP (mV) | 0.7 ± 0.1 | 0.5 ± 0.1 | 0.4 ± 0.1 | NS | |
| ds | PMv-M1 (%) | 125 ± 9 * | 142 ± 6 | 105 ± 7 | <0.001 |
| PMd-M1 (%) | 51 ± 7 * | 92 ± 7 | 105 ± 9 | NS0.06 | |
| SMA (%) | 53 ± 9 * | 94 ± 6 | 106 ± 8 | NS0.07 | |
| PPC-M1 (%) | 123 ± 11 * | 148 ± 6 | 105 ± 7 | <0.001 | |
| pp | LICI (%) | 60 ± 7 * | 94 ± 13 | 107 ± 5 | NS |
| SICF (%) | 129 ± 9 * | 144 ± 13 | 167 ± 5 | NS0.06 | |
| VMI40 (%) | 51 ± 8 * | 79 ± 6 | 97 ± 9 | <0.001 | |
| VMI100 (%) | 112 ± 5 * | 122 ± 6 | 108 ± 9 | 0.01 | |
| tACS | VEP latency (ms) | 102 ± 7 | 115 ± 2 | 121 ± 3 | NS |
| VEP amplitude ( μV) | 19 ± 3 | 12 ± 2 | 8 ± 1 | NS | |
| ERPLLO latency (ms) | 303 ± 10 * | 340 ± 15 | Absent | <0.001 | |
| ERPLLO amplitude ( μV) | 17 ± 8 * | 6 ± 4 | Absent | 0.002 | |
| ERPLT latency (ms) | 331 ± 12 * | Absent | Absent | NS | |
| ERPLT amplitude ( μV) | 10 ± 4 * | Absent | Absent | NS |
sp: single pulse TMS; ds: dual-site TMS; pp: paired-pulse TMS.
We observed significant real_tDCS after-effects in HC and MCS patients, whereas UWS did not show any significant after-effect at group level. The tDCS_alone induced after-effects that were similar to the real_protocol but non-significant and limited to the MEP amplitude increase and the PPC-M1 potentiation. The tACS_alone and the sham_protocol were totally ineffective
|
| real_protocol | ||||
| HC t (1,6) , | MCS t (1,6) , | ||||
| MEP amplitude | 3.0 <0.001 | T0 | 3.2, 0.02 | 3, 0.01 | |
| T30 | 2.7, 0.03 | NS | |||
| T60 | NS | ||||
| ERPLLO amplitude | 3.2, <0.001 | T0 | 6.1, <0.001 | 2.5, 0.04 | |
| T30 | 6, <0.001 | NS | |||
| T60 | NS | ||||
| ERPLT amplitude | NS | T0 | 6, <0.001 | NS | |
| T30 | 5.1, 0.005 | NS | |||
| T60 | NS | ||||
| PMd-M1 % | 1.7, 0.04 | T0 | 6.4, <0.001 | 2.3, 0.04 | |
| T30 | 3.2, 0.02 | NS | |||
| T60 | NS | ||||
| PPC-M1 % | 3.8, <0.001 | T0 | 3.2, 0.02 | 2.3, 0.04 | |
| T30 | 2.4, 0.04 | NS | |||
| T60 | NS | ||||
| SICF % | 1.8, 0.02 | T0 | 2.9, 0.01 | 2.8, 0.01 | |
| T30 | 2.7, 0.03 | NS | |||
| T60 | NS | ||||
| VMI40 % | 7.9, <0.001 | T0 | 9.1, <0.001 | 3.2, 0.02 | |
| T30 | 6.3, 0.003 | NS | |||
| T60 | NS | ||||
| VMI100 % | 5.4, <0.001 | T0 | 3.8, 0.003 | 3.2, 0.02 | |
| T30 | 3.2, 0.02 | NS | |||
| T60 | NS | ||||
| SMA-M1 % | 2.6, <0.001 | T0 | 2.8, 0.01 | 2.8, 0.01 | |
| T30 | 2.7, 0.03 | NS | |||
| T60 | NS | ||||
Fig.2The electrophysiological after-effects following the real_protocol (the ineffective protocols are not shown), which were significant up to T30 for HC ( *), and to T0 for MCS (#). UWS patients did not show any significant after-effects (except for n. 3). Indeed, UWS showed before and after the real_protocol a wide impairment of cortical excitability and connectivity, whereas MCS showed an amelioration of such parameters. Values are expressed as percent of the unconditioned one. Error bars refer to standard error.